PortfoliosLab logo
Kintor Pharmaceutical Ltd (9939.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

KYG5273B1077

Highlights

Market Cap

HK$543.06M

Year Range

HK$0.79 - HK$1.84

Target Price

HK$13.78

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Kintor Pharmaceutical Ltd (9939.HK) returned 29.90% year-to-date (YTD) and 12.50% over the past 12 months.


9939.HK

YTD

29.90%

1M

14.55%

6M

13.51%

1Y

12.50%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of 9939.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-8.25%24.72%17.12%-7.69%5.00%29.90%
2024-25.77%8.26%-34.35%8.14%30.11%-14.05%-1.92%-10.78%28.57%-6.84%0.00%-11.01%-40.49%
20235.79%-7.10%-33.37%-16.12%-29.02%-6.51%11.42%-13.00%-21.26%-4.38%-24.81%-17.26%-83.45%
2022-36.75%62.98%-23.11%132.82%5.51%-21.92%-19.25%-2.91%-24.01%11.67%6.91%-25.94%-19.92%
202133.27%21.09%115.94%93.42%-3.97%-6.94%17.22%5.62%-33.01%-25.74%45.23%-78.17%17.59%
2020-32.93%4.44%2.66%-8.54%-35.36%-15.32%8.27%24.82%-51.35%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 9939.HK is 68, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of 9939.HK is 6868
Overall Rank
The Sharpe Ratio Rank of 9939.HK is 5959
Sharpe Ratio Rank
The Sortino Ratio Rank of 9939.HK is 7575
Sortino Ratio Rank
The Omega Ratio Rank of 9939.HK is 7474
Omega Ratio Rank
The Calmar Ratio Rank of 9939.HK is 6868
Calmar Ratio Rank
The Martin Ratio Rank of 9939.HK is 6666
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Kintor Pharmaceutical Ltd (9939.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Kintor Pharmaceutical Ltd Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: 0.17
  • All Time: -0.39

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Kintor Pharmaceutical Ltd compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Kintor Pharmaceutical Ltd doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Kintor Pharmaceutical Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Kintor Pharmaceutical Ltd was 99.05%, occurring on Sep 11, 2024. The portfolio has not yet recovered.

The current Kintor Pharmaceutical Ltd drawdown is 98.52%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.05%Sep 2, 2021744Sep 11, 2024
-66.33%May 25, 2020123Nov 19, 202079Mar 16, 2021202
-34.6%May 24, 202118Jun 17, 202123Jul 21, 202141
-24.9%Mar 23, 20213Mar 25, 202113Apr 16, 202116
-22.89%Jul 22, 20214Jul 27, 202126Sep 1, 202130

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Kintor Pharmaceutical Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Kintor Pharmaceutical Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for 9939.HK relative to other companies in the Biotechnology industry. Currently, 9939.HK has a P/S ratio of 108.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for 9939.HK in comparison with other companies in the Biotechnology industry. Currently, 9939.HK has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items